


hossam maghraby



شبكة المعلومات الجامعية

# بسم الله الرحمن الرحيم




**hossam maghraby**



شبكة المعلومات الجامعية



# شبكة المعلومات الجامعية التوثيق الالكتروني والميكرو فيلم





hossam maghraby



شبكة المعلومات الجامعية

# جامعة عين شمس

التوثيق الإلكتروني والميكروفيلم

## قسم

نقسم بالله العظيم أن المادة التي تم توثيقها وتسجيلها  
علي هذه الأقراص المدمجة قد أعدت دون أية تغيرات



## يجب أن

تحفظ هذه الأقراص المدمجة بعيدا عن الغبار



**hossam maghraby**



شبكة المعلومات الجامعية



# بعض الوثائق الأصلية تالفة






**hossam maghraby**



شبكة المعلومات الجامعية



**بالرسالة صفحات  
لم ترد بالأصل**



بِسْمِ اللَّهِ الرَّحْمَنِ الرَّحِيمِ

**A STUDY OF THE EXTENDED-SPECTRUM  $\beta$ -  
LACTAMASES PRODUCED BY  
*ENTEROBACTERIACEAE* VERSUS DIFFERENT  
CEPHALOSPORINS**

*A Thesis Presented By*

**Nelly Mostafa Abdel-Moneim Mohamed**

B. Pharm. Sci., University of Alexandria (1996)

M. Pharm. Sci. (Pharm. Microbiol.)

University of Alexandria (2000)

*For the Degree of*

**DOCTOR OF PHILOSOPHY**

*In*

**Pharmaceutical Sciences  
(Pharmaceutical Microbiology)**

*Under the Supervision of*

***Prof. Dr. Mansour E. Aggag***

Professor of Pharmaceutical  
Microbiology  
Faculty of Pharmacy

***Prof. Dr. Mohamed A.  
Fawzi***

Professor and head of Pharmaceutical  
Microbiology Department  
Faculty of Pharmacy

***Dr. Nadia M. El-Guink***

Lecturer of Pharmaceutical  
Microbiology  
Faculty of Pharmacy

***Dr. Hesham M. Saeed***

Lecturer of Biochemistry  
Institute of Graduate Studies and  
Research

Department of Pharmaceutical Microbiology  
Faculty of Pharmacy  
University of Alexandria  
Egypt  
2004

B1.7756

**Approved by**

**Committee in charge**

.....

.....

.....

.....



## ACKNOWLEDGEMENTS

I would like to seize the opportunity to extend my deepest gratitude and warmest regards to *Prof. Dr. Mansour E. Aggag*, Professor of Pharmaceutical Microbiology, Faculty of Pharmacy, University of Alexandria, for his instructive advice, his fruitful discussions, his guiding amendments and endless support. I owe him great appreciation for what I have learned and what I have achieved.

I would like to express my infinite appreciation and profound thanks to *Prof. Dr. Mohamed A. Fawzy*, Professor of Pharmaceutical Microbiology, Faculty of Pharmacy, University of Alexandria, for his constructive ideas, devotion in solving many of the problems encountered throughout the course of this study and sincerity in giving me vital guidance and supervision during the entire work.

I am greatly indebted to *Dr. Nadia M. El-Guink*, Lecturer of Pharmaceutical Microbiology, Faculty of Pharmacy, University of Alexandria. I would like to express my deepest thanks for her cooperation, valuable suggestions, sincere encouragement and indispensable help in revising the manuscript.

I feel greatly thankful to *Dr. Hesham M. Saeed*, Lecturer of Biochemistry and Biotechnology, Institute of Graduate Studies and Research, University of Alexandria, for his generous help, patience, keen interest, valuable effort and advice in the molecular biology part of this thesis.

I would like to thank my colleagues, secretarial staff, technicians and workers of the Microbiology Department for provided assistance and generous help.

Finally, I would like to acknowledge a warm debt of gratitude to my dearest parents and my husband whose cordial encouragement and loving support were of great value in accomplishing this thesis.

*Nelly M. Abdel-Moneim*

# LIST OF ABBREVIATIONS

Abbr.	Name	Abbr.	Name
AK	Amikacin	Ent <sub>1</sub> , Ent <sub>2</sub>	<i>Enterobacter cloacae</i>
AMP	Ampicillin	K <sub>1</sub> -K <sub>41</sub>	<i>Klebsiella pneumoniae</i>
AMC	Amoxicillin/clavulanate	Pr <sub>1</sub>	<i>Proteus mirabilis</i>
ATM	Aztreonam	Ps <sub>1</sub> -Ps <sub>8</sub>	<i>Pseudomonas aeruginosa</i>
CAZ	Ceftazidime	API	Analytical Profile Index
CFP	Cefoperazone	BLAST	Basic Local Alignment Search Tool
CIP	Ciprofloxacin	bla <sub>SHV</sub>	β-lactamase SHV gene
Clav	Potassium clavulanate	bla <sub>TEM</sub>	β-lactamase TEM gene
CN	Gentamicin	bp	base pair
CPD	Cefpodoxime	CFU	Colony Forming Unit
CPO	Cefpirome	ESBLs	Extended-Spectrum β-Lactamases
CRO	Ceftriaxone	Etest	Epsilometer test
CTX	Cefotaxime	GFX	Glass Fiber Matrix
CXM	Cefuroxime	IC <sub>50</sub>	50% Inhibitory Concentration
FEP	Cefepime	ICU	Intensive Care Unit
IPM	Imipenem	Kbp	Kilobase pair
KF	Cephalothin	K <sub>m</sub>	Michaelis constant
NA	Nalidixic acid	MIC	Minimum Inhibitory Concentration
OFX	Ofloxacin	PBPs	Penicillin Binding Proteins
PRL	Piperacillin	PCR	Polymerase Chain Reaction
S	Streptomycin	pI	Isoelectric point
SAM	Ampicillin/sulbactam	RFLP	Restriction Fragment Length Polymorphism
SXT	Co-trimoxazole	SDS	Sodium Dodecyl Sulphate
TE	Tetracycline	TAE	Agarose gel electrophoresis buffer (Tris-Acetate-Edetate)
TOB	Tobramycin	TE	Tris-EDTA buffer
C <sub>1</sub> , C <sub>2</sub>	<i>Citrobacter freundii</i>	UV	Ultraviolet radiations
E <sub>1</sub> -E <sub>21</sub>	<i>Escherichia coli</i>	V <sub>max</sub>	Maximum velocity



# CONTENTS

CHAPTER	PAGE
I. INTRODUCTION.....	1
II. AIM OF THE WORK.....	54
III. MATERIALS AND METHODS .....	55
- Materials .....	55
- Methods.....	65
IV. RESULTS.....	90
V. DISCUSSION.....	229
VI. SUMMARY AND CONCLUSION.....	252
VII. REFERENCES .....	258
APPENDIX	
ARABIC SUMMARY	

## LIST OF TABLES

Table	Page
(1) Frequency of the 75 isolates.	91
(2) Types and number of the isolated organisms from different clinical specimens.	92
(3) Biochemical tests used for the identification of the tested isolates.	94
(4) Results of the API 20E identification for selected isolates	98
(5) Interpretation of the API 20E results using the API index.	99
(6) Antibiotic resistance of the tested isolates.	101
(7) The percentage of tested isolates susceptible to different cephalosporin generations.	103
(8) Multiple resistance pattern of the tested isolates to different cephalosporin generations.	105
(9) $\beta$ -lactam/ $\beta$ -lactam co-resistance against the tested isolates	106
(10) $\beta$ -lactam/non- $\beta$ -lactam co-resistance against the tested isolates	107
(11) MIC range, MIC <sub>50</sub> and MIC <sub>90</sub> of different antibiotics against the tested isolates.	111
(12) Minimum inhibitory concentrations of different antibiotics against 75 clinical isolates.	113
(13) $\beta$ -lactamase production by the iodometric method for the isolated <i>Enterobacteriaceae</i> and <i>Ps. aeruginosa</i> .	115

Table		Page
(14)	Inhibition zone diameters for possible ESBL-producing isolates using the Kirby-Bauer disc-diffusion method.	117
(15)	Effect of potassium clavulanate on the MIC of cefotaxime and ceftazidime against possible ESBL-producing isolates.	118
(16)	Inhibition zone diameters and zone augmentation for the detection of ESBL-producing isolates using the inhibitor-potentiated disc-diffusion test.	122
(17)	Detection of ESBL production using Etest ESBL strips.	125
(18)	Plasmid profiles of the ESBL-producing isolates.	129
(19)	Conjugation frequency and plasmid profile for the obtained transconjugants.	132
(20)	Antibiotic susceptibility of the recipient <i>E. coli</i> K-12 UB5202, donors: K <sub>24</sub> , K <sub>26</sub> , K <sub>41</sub> and their corresponding transconjugants.	133
(21)	Transformation rate and plasmid profile for the obtained transformants.	135
(22)	Antibiotic resistance pattern of the ESBL-producing isolates and their corresponding transformants.	137
(23)	Minimum inhibitory concentration (MIC) of the ESBL-producing isolates, their corresponding transconjugants and transformants.	139
(24)	Substrate profile of the ESBL produced by K <sub>11</sub> isolate.	143
(25)	Substrate profile of the ESBL produced by K <sub>26</sub> isolate.	143



Table		Page
(26)	Substrate profile of the ESBL produced by K <sub>29</sub> isolate.	144
(27)	Substrate profile of the ESBL produced by E <sub>9</sub> isolate.	144
(28)	Substrate profile of the ESBL produced by E <sub>10</sub> isolate.	145
(29)	Relative specific activity of the ESBLs with reference to cephaloridine.	147
(30)	Effect of different cephaloridine concentrations on the activity of the ESBLs produced by the tested isolates.	148
(31)	Effect of different cefuroxime concentrations on the activity of the ESBLs produced by the tested isolates.	149
(32)	Effect of different cefotaxime concentrations on the activity of the ESBLs produced by the tested isolates.	150
(33)	Effect of different ceftazidime concentrations on the activity of the ESBLs produced by the tested isolates.	151
(34)	Effect of different cefepime concentrations on the activity of the ESBLs produced by the tested isolates.	152
(35)	Kinetic parameters of the ESBLs against different cephalosporin generations.	159
(36)	Relative kinetic parameters of the tested ESBLs with respect to cephaloridine.	161